Perceptive Advisors LLC Cytom X Therapeutics, Inc. Transaction History

Perceptive Advisors LLC

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 15, 2021	SELL	$4.32 - $6.43 $7.09 Million - $10.6 Million	-1,640,957 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$6.33 - $9.91 $3.25 Million - $5.08 Million	-513,017 Reduced 23.82%	1,640,957 $10.4 Million
Q1 2021 May 17, 2021	SELL	$6.6 - $9.0 $2.79 Million - $3.81 Million	-423,069 Reduced 16.42%	2,153,974 $16.7 Million
Q2 2020 Aug 14, 2020	SELL	$7.4 - $14.64 $5.01 Million - $9.91 Million	-676,880 Reduced 20.8%	2,577,043 $21.5 Million
Q3 2019 Nov 14, 2019	BUY	$7.38 - $12.25 $738,000 - $1.23 Million	100,000 Added 3.17%	3,253,923 $24 Million
Q2 2019 Aug 14, 2019	SELL	$9.35 - $11.41 $187,000 - $228,200	-20,000 Reduced 0.63%	3,153,923 $35.4 Million
Q1 2019 May 15, 2019	BUY	$9.5 - $19.16 $2.49 Million - $5.02 Million	262,208 Added 9.01%	3,173,923 $34.1 Million
Q4 2018 Feb 14, 2019	BUY	$12.69 - $18.61 $3.17 Million - $4.65 Million	250,000 Added 9.39%	2,911,715 $43.6 Million
Q3 2018 Nov 14, 2018	BUY	$18.04 - $26.41 $13.3 Million - $19.5 Million	740,000 Added 38.51%	2,661,715 $49.2 Million
Q2 2018 Aug 14, 2018	SELL	$21.38 - $29.68 $6.14 Million - $8.52 Million	-287,097 Reduced 13.0%	1,921,715 $43.9 Million
Q1 2018 May 15, 2018	SELL	$21.76 - $34.22 $6.13 Million - $9.64 Million	-281,569 Reduced 11.31%	2,208,812 $62.8 Million
Q4 2017 Feb 14, 2018	BUY	$19.0 - $23.09 $20.9 Million - $25.4 Million	1,100,000 Added 79.12%	2,490,381 $52.6 Million
Q3 2017 Nov 14, 2017	BUY	$13.53 - $18.17 $18.8 Million - $25.3 Million	1,390,381	1,390,381 $25.3 Million

49.4M

112K

8.3K

Ticker CTMX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 65,950,200
Market Cap $55.4M
Description
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical...

Get notified when there are updates to the investment portfolio of Perceptive Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Perceptive Advisors LLC with notifications on news.